Table 1. Patient characteristics, symptoms of COVID-19, treatment modalities, and sampling time points of three SARS-CoV-2–infected patients.
| COSCA1 | COSCA2 | COSCA3 | ||
| Patient characteristics | ||||
| Age (years) | 47 | 44 | 69 | |
| Gender | Male | Female | Male | |
| Comorbidities | None | None | None | |
| Symptoms, from onset to relief, days | ||||
| Fever (>38°C) | 4–10 | 1–4 | 6–18 | |
| Coughing | 2–35 | 3–17 | 1–20 | |
| Sputum production | 2–35 | No | 1–20 | |
| Dyspnea | 4–24 | No | No | |
| Sore throat | 1–5 | 5–17 | No | |
| Rhinorrhea | 2–34 | 5–17 | No | |
| Anosmia | No | 5–17 | No | |
| Myalgia | No | 1–4 | 6–18 | |
| Headache | No | No | 1–18 | |
| Other | No | No | Delirium | |
| Treatment modalities, treatment period, days | ||||
| Hospital admission | No | No | 8–24 | |
| ICU admission | No | No | 11–18 | |
| Oxygen therapy | No | No | 8–24 | |
| Intubation | No | No | 11–16 | |
| Dialysis | No | No | No | |
| Drug therapy | ||||
| Antiviral | No | No | No | |
| Antibiotic | No | No | Cefotaxime, 8–12 Ciprofloxacin, 8–11 | |
| Immunomodulatory | No | No | No | |
| NSAIDs | No | No | No | |
| Sampling time point, days after symptom onset | 27 | 28 | 23 | |